Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | GPR183 | P32249 | 2/20 | 0.34 |
| ▸ | POLQ | O75417 | 4/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272016 | 0.83 | POLQ (0.49) | PTGDR2POLQEPHX2 | |
| SCHEMBL22235493 | 0.80 | POLQ (0.42) | PTGDR2KDM1AGPR183POLQEPHX2 | |
| SCHEMBL9957201 | 0.78 | MAOB (0.49) | POLQEPHX2KMT2A | |
| SCHEMBL16770736 | 0.77 | KDM1A (0.42) | PTGDR2KDM1AGPR183POLQEPHX2 | |
| SCHEMBL1988822 | 0.76 | SETDB1 (0.49) | EPHX2 | |
| SCHEMBL20196946 | 0.75 | KDM1A (0.43) | PTGDR2KDM1AGPR183S1PR4EPRS1 | |
| SCHEMBL30626575 | 0.75 | KDM1A (0.43) | PTGDR2KDM1AGPR183S1PR4EPRS1 | |
| SCHEMBL20563511 | 0.74 | RXRA (0.46) | PTGDR2KDM1APOLQEPRS1 | |
| SCHEMBL29754255 | 0.74 | RXRA (0.46) | PTGDR2KDM1APOLQEPRS1 | |
| SCHEMBL271294 | 0.74 | NPSR1 (0.36) | RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220056-B1 | HERBICIDAL COMPOUNDS | SYNGENTA LTD (GB) | 2015-09-30 | — | — | EP | disclosed |
| EP-2220056-B1 | HERBICIDAL COMPOUNDS | SYNGENTA LTD (GB) | 2015-09-30 | — | — | EP | disclosed |
| US-8133849-B2 | Herbicidal compounds | SYNGENTA LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-8133849-B2 | Herbicidal compounds | SYNGENTA LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-8133849-B2 | Herbicidal compounds | SYNGENTA LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-20100323889-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323889-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323889-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| CN-101910138-A | Herbicidal compounds | SYNGENTA LTD | 2010-12-08 | — | — | CN | disclosed |
| EP-2220056-A1 | HERBICIDAL COMPOUNDS | Syngenta Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063180-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009063180-A1 | HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323889-A1 | HERBICIDAL COMPOUNDS | CBR3, DDT, CBR1 | PTGDR2 2356/4885KDM1A 446/4885GPR183 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.